Regeneron Pharmaceuticals Inc (REGN)

Sep 28, 2026

Regeneron Pharmaceuticals' stock is falling due to positive Phase 3 trial data from Kodiak Sciences Inc. for its wet age-related macular degeneration (wAMD) drug, Zenkuda. Zenkuda demonstrated non-inferior vision gains compared to Regeneron's Eylea, and Kodiak is exploring a six-month dosing schedule, which could set a new benchmark in wAMD treatment. Despite the approval of Eylea HD, competitive pressures from such advancements are impacting Regeneron's Eylea sales.

Sep 28, 2026

Mirum Pharmaceuticals received FDA approval for Atebrioz (zilurgisertib), an ALK2 inhibitor, to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare bone-forming disease. This approval marks the third treatment option available for FOP patients, joining Regeneron’s Pasatru and Ipsen’s Sohonos, which were recently approved. Atebrioz works by inhibiting the ALK2 protein, responsible for abnormal bone growth in FOP, and demonstrated an 81% reduction in new lesion volume in its Phase 2 study.

Sep 28, 2026

Kodiak Sciences announced positive Phase 3 DAYBREAK trial results for its eye drugs, Zenkuda and tabirafusp-ted, for wet age-related macular degeneration (wAMD). The drugs demonstrated non-inferior vision gains compared to Regeneron's Eylea and showed favorable safety profiles. Kodiak plans to submit a multi-indication biologics license application for Zenkuda in Q4 2026.

Sep 28, 2026

The FDA has approved Atebrioz (zilurgisertib) tablets, developed by Incyte and licensed to Mirum Pharmaceuticals, as a new once-daily oral treatment for fibrodysplasia ossificans progressiva (FOP). This medication, an ALK2 inhibitor, significantly reduces new abnormal bone formation in adults and children 12 and older by targeting the genetic mutation causing the condition. The approval was based on clinical study results showing a substantial decrease in HO lesion volume compared to a placebo, and the FDA awarded Incyte a Rare Pediatric Disease Priority Review Voucher.

Sep 28, 2026

The immunology and inflammation (I&I) market is a significant therapeutic area in biopharma, with companies like AbbVie, Sanofi, and Regeneron having blockbuster drugs. As key drugs near the end of their exclusivity, big pharma and smaller specialists are pursuing novel targets and improving existing ones to capitalize on this massive market. This article highlights six major immunology targets and the companies developing treatments, including FcRn, STAT6, and next-generation IL-13/IL-4 blockers, aiming for improved efficacy or more convenient dosing.

Sep 26, 2026

Sarepta Therapeutics' stock dropped 7.2% despite settling a patent infringement lawsuit with REGENXBIO and the University of Pennsylvania regarding ELEVIDYS and AAVrh74-based gene therapies. The settlement, involving a US$39.0 million payment, provides Sarepta with freedom to operate but shifts investor focus back to ELEVIDYS's clinical performance, safety, and commercial execution. Analysts offer varying forecasts for Sarepta's future revenue and earnings, with some predicting a significant upside while others remain cautious due to reliance on ELEVIDYS.

Sep 26, 2026

Wall Street Zen has upgraded Adicet Bio (NASDAQ:ACET) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $46.80. The clinical-stage biotechnology company's shares opened up 9.1% at $9.02, despite missing its latest earnings estimate. Institutional investors and hedge funds own a significant 83.89% of the company.

Sep 25, 2026

REGENXBIO Inc. reported new three-year follow-up data from its ALTITUDE trial, showing that six out of ten higher-dose participants experienced a significant improvement in diabetic retinopathy severity. This data supports the ongoing Phase IIb/III NAAVIGATE trial, which is testing the gene therapy sura-vec against a sham control. The company expects topline results from its ATMOSPHERE and ASCENT trials for wet age-related macular degeneration in Q4 2026 and projects a cash runway into Q4 2027.

Sep 25, 2026

Sanofi is diversifying its revenue streams beyond its top-selling immunology drug, Dupixent, which currently accounts for 42% of its first-half 2026 revenues. The company is experiencing strong uptake for new medicines like Altuviiio, Ayvakit, and Sarclisa, with new and acquired drug sales rising 48.3% in Q2. Sanofi anticipates its new pharma launches to generate approximately €10 billion in annual sales by 2030, aiming to broaden its revenue base and decrease its reliance on Dupixent.

Sep 24, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced it will release its third-quarter 2026 financial and operating results on October 30, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day to discuss the results. Interested participants can access the webcast via Regeneron's investor relations page or register in advance for telephone participation.

Sep 24, 2026

Merck announced that both doses of its drug remigromig met the BRUNELLO trial's noninferiority goal against ranibizumab for diabetic macular edema. While the drug showed promise in vision improvement, the company flagged higher rates of eye complications and adverse event discontinuations compared to the control group. More detailed safety and efficacy data are expected to be presented at the American Academy of Ophthalmology meeting on October 10.

Sep 23, 2026

State Street Corp increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 3.6% in the second quarter, now owning 4.83 million shares valued at approximately $3.01 billion. Regeneron exceeded quarterly earnings expectations with $14.29 EPS and $4.29 billion in revenue, showing a 16.7% year-over-year increase. The stock holds a "Moderate Buy" consensus rating with an average analyst target of $802.18 and offers a quarterly dividend of $0.94.

Sep 22, 2026

Regeneron Pharmaceuticals' shares have dropped significantly from their all-time highs of two years ago, now trading below $800. The article explores whether the stock is a good buy, highlighting strong Q2 revenue driven by Dupixent, the strategic launch of higher-dose Eylea HD to combat biosimilar competition, and promising pipeline candidates like the weight-loss medicine olatorepatide. Given the company's financial improvements, long-term strategy for key drugs, and pipeline, the author suggests Regeneron's shares are attractive at current levels.

Sep 22, 2026

Regeneron's shares have dropped significantly, now trading below $800, leading to questions about its value. The company reported strong Q2 revenue growth driven by Dupixent and is mitigating Eylea's patent cliff impact with Eylea HD. Regeneron also has promising pipeline candidates like the weight-loss drug olatorepatide, suggesting a bright future despite market challenges.

Sep 22, 2026

Andra AP fonden significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 583.2% in the second quarter, now holding 28,912 shares valued at $18 million. Institutional investors collectively own 83.31% of the company. Regeneron recently reported strong quarterly earnings, beating consensus estimates with $14.29 EPS and $4.29 billion in revenue, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $802.18, despite recent insider share sales.

Sep 22, 2026

This article highlights four biotech stocks – Kodiak Sciences (KOD), Celldex Therapeutics (CLDX), Rapport Therapeutics (RAPP), and Vaxcyte (PCVX) – that have significant clinical readouts anticipated in the fall, which could dramatically impact their valuations. These readouts cover various therapeutic areas including ophthalmology, immunology, neuroscience, and vaccines. The companies' future prospects hinge on these study results, making them key watch targets for investors.

Sep 22, 2026

This article analyzes Boston Scientific (BSX) within the context of the broader healthcare stocks market, highlighting how specific clinical and regulatory catalysts have revived interest in medical technology. It emphasizes the importance of a company-specific reading, rather than treating BSX merely as a sector proxy, to understand its performance in medical devices across various specialties. The piece concludes by noting that while market enthusiasm is evident, investors should look for concrete operational updates from Boston Scientific to confirm whether the current attention is supported by execution.

Sep 21, 2026

Regeneron Pharmaceuticals Inc. (REGN) stock gained 1.70% on Monday, closing at $798.17. Despite this daily gain and a positive trading session for the broader market, the stock underperformed compared to its competitors. Regeneron is currently 7.12% below its 52-week high of $859.34, reached on September 3rd.

Sep 18, 2026

Analysts have issued a "Moderate Buy" consensus rating for Adicet Bio, Inc. (NASDAQ:ACET) with an average 12-month price target of $46.80, significantly higher than its current trading price of $8.87. The company recently reported a quarterly loss of $1.99 per share, missing consensus estimates by $0.30. Institutional investors own a substantial 83.89% of the stock, with several firms establishing new positions.

Sep 16, 2026

Gossamer Bio, a clinical-stage biopharmaceutical company, announced the appointment of Greg Ciongoli to its Board of Directors, effective September 16, 2026. Mr. Ciongoli, founder of Adiumentum Capital Management and former Partner at the Baupost Group, will also join the Audit Committee. His extensive investment background is expected to be a significant asset as the company advances seralutinib for pulmonary hypertension towards potential FDA approval.

Sep 15, 2026

Regeneron Pharmaceuticals Inc. (REGN) stock fell 2.47% to $774.11 on Tuesday, underperforming the broader market as the S&P 500 Index (SPX) dropped 0.45% and the Dow Jones Industrial Average (DJIA) fell 0.63%. The company's stock closed 9.92% below its 52-week high of $859.34, reached on September 3rd.